Cargando…

ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression

Previously we found that the estrogen receptor (ER) related factor ERRF regulates cell proliferation and tumor growth, and its expression is positively associated with ER status and better survival but inversely associated with ERBB2 (also named HER2) status in breast cancer. Here we report that ERR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Leilei, Zhang, Baotong, Zhang, Shiying, Ci, Xinpei, Wu, Qiao, Ma, Gui, Luo, Ang, Fu, Liya, King, Jamie L., Nahta, Rita, Dong, Jin-Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482638/ https://www.ncbi.nlm.nih.gov/pubmed/28415602 http://dx.doi.org/10.18632/oncotarget.16425

Ejemplares similares

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014)

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
por: Yallowitz, Alisha, et al.
Publicado: (2018)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
por: Raja Sharin, Raja Nur Firzanah Syaza, et al.
Publicado: (2022)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells
por: Komurov, Kakajan, et al.
Publicado: (2012)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2
por: Karakashev, Sergey V., et al.
Publicado: (2015)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway
por: Yang, Zi-Yan, et al.
Publicado: (2020)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
por: Janni, Wolfgang, et al.
Publicado: (2014)

Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice
por: Ma, Zhikun, et al.
Publicado: (2017)

Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models
por: Awah, Chidiebere U., et al.
Publicado: (2023)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases
por: Spencer, Kathryn S.R., et al.
Publicado: (2000)

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
por: Gautam, Shailendra K., et al.
Publicado: (2020)

Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma
por: Meyers, Nora, et al.
Publicado: (2020)

miR-1296-5p decreases ERBB2 expression to inhibit the cell proliferation in ERBB2-positive breast cancer
por: Chen, Gang, et al.
Publicado: (2017)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition
por: Thakur, Varsha, et al.
Publicado: (2017)

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
por: Henjes, F, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j4iimlgtkchihet2jklup1pgjf